Literature DB >> 28879509

IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA.

Paula Piñero1,2, Oriol Juanola1,2,3, Ana Gutiérrez1,2,4, Pedro Zapater1,2,5, Paula Giménez1,2, Anna Steinert6,7, Laura Sempere2,4, José M González-Navajas1,2, Jan H Niess6,7, Rubén Francés8,9,10.   

Abstract

Interleukin IL26 supports killing of microbes and the innate sensing of bacterial-derived DNA (bactDNA). We evaluated the relationship between IL26 serum levels and bactDNA translocation in Crohn's disease (CD). We ran a prospective study on CD patients in remission. IL26 common polymorphisms, serum cytokines and complement protein, amplified-bactDNA, and anti-TNF-α were evaluated. In vitro PBMC analysis was performed. Three hundred and thirteen patients were included (mean CDAI: 83.6 ± 32.8; mean fecal calprotectin: 55.4 ± 35.3 μg/g). A total of 106 patients (33.8%) showed bactDNA and 223 patients (71%) had a varIL26 genotype. BactDNA significantly correlated with increased IL26 levels compared with bactDNA-negative patients. PBMCs from varIL26 patients significantly reduced E. coli killing capacity compared with wtIL26-genotyped patients. The stimulation with a recombinant IL26 protein reduced pro-inflammatory cytokines in response to E. coli in the varIL26 cell supernatants. Serum anti-TNF-α levels in varIL26 vs wtIL26-genotyped patients on biologics were significantly lower in the presence of bactDNA. Cells from varIL26 vs wtIL26-genotyped patients cultured with E. coli DNA and infliximab showed a significant decrease in free anti-TNF-α concentration. A varIL26 genotype was associated with the initiation of anti-TNF-α in CD patients during the 6-month follow-up. IL26 polymorphisms may prevent bactDNA clearance and identify CD patients with a worse inflammatory evolution and response to therapy. KEY MESSAGES: BactDNA translocation in CD is associated with an increased risk of relapse. IL26 is sensitive to bactDNA and modulates the inflammatory response in CD patients. The varIL26 genotype is associated with reduced PMN capacity to kill bacteria. A varIL26 genotype is associated with decreased levels of anti-TNF-α in CD patients. IL26 may help explain the role of bactDNA as a risk factor of flare in CD patients.

Entities:  

Keywords:  Bacterial translocation; Crohn’s disease; Interleukin 26

Mesh:

Substances:

Year:  2017        PMID: 28879509     DOI: 10.1007/s00109-017-1585-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  29 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 2.  From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation.

Authors:  Bruce E Sands
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

3.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

4.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

5.  Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease.

Authors:  Ana Gutiérrez; Pedro Zapater; Oriol Juanola; Laura Sempere; Marifé García; Raquel Laveda; Antonio Martínez; Michael Scharl; José M González-Navajas; José Such; Reiner Wiest; Gerhard Rogler; Rubén Francés
Journal:  Am J Gastroenterol       Date:  2016-02-23       Impact factor: 10.864

6.  CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation.

Authors:  Florian Obermeier; Nadja Dunger; Ulrike G Strauch; Claudia Hofmann; Andre Bleich; Nicole Grunwald; Hans J Hedrich; Elisabeth Aschenbrenner; Brigitte Schlegelberger; Gerhard Rogler; Jürgen Schölmerich; Werner Falk
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

7.  Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis.

Authors:  Rubén Francés; José M González-Navajas; Pedro Zapater; Carlos Muñoz; Rocío Caño; Sonia Pascual; Dorkas Márquez; Francia Santana; Miguel Pérez-Mateo; José Such
Journal:  J Clin Immunol       Date:  2007-04-03       Impact factor: 8.317

Review 8.  Interactions between the host innate immune system and microbes in inflammatory bowel disease.

Authors:  Clara Abraham; Ruslan Medzhitov
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

9.  T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26.

Authors:  Stephan Meller; Jeremy Di Domizio; Kui S Voo; Heike C Friedrich; Georgios Chamilos; Dipyaman Ganguly; Curdin Conrad; Josh Gregorio; Didier Le Roy; Thierry Roger; John E Ladbury; Bernhard Homey; Stanley Watowich; Robert L Modlin; Dimitrios P Kontoyiannis; Yong-Jun Liu; Stefan T Arold; Michel Gilliet
Journal:  Nat Immunol       Date:  2015-07-13       Impact factor: 25.606

10.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

View more
  4 in total

Review 1.  IL-26, a Cytokine With Roles in Extracellular DNA-Induced Inflammation and Microbial Defense.

Authors:  Vincent Larochette; Charline Miot; Caroline Poli; Elodie Beaumont; Philippe Roingeard; Helmut Fickenscher; Pascale Jeannin; Yves Delneste
Journal:  Front Immunol       Date:  2019-02-12       Impact factor: 7.561

2.  Interleukin-26 Expression in Inflammatory Bowel Disease and Its Immunoregulatory Effects on Macrophages.

Authors:  Dongjuan Song; Lijie Lai; Juntao Lu; Jinlu Tong; Zhihua Ran
Journal:  Front Med (Lausanne)       Date:  2022-04-06

Review 3.  The Interleukin-20 Cytokines in Intestinal Diseases.

Authors:  Jan Hendrik Niess; Petr Hruz; Tanay Kaymak
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

4.  Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease.

Authors:  Beatriz Orts; Ana Gutierrez; Lucía Madero; Laura Sempere; Ruben Frances; Pedro Zapater
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.